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Abstract..  
 
Background: Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with 
median survival of 20% at 1 year. We conducted a retrospective study to assess the 
efficacy and tolerability of nab-paclitaxel (NP)-based second-line chemotherapy in 
metastatic PDAC. Patients and Methods: Indiana University Simon Cancer Center 
pancreatic cancer program was used to identify patients with metastatic PDAC who 
received any second-line chemotherapy. Demographic, clinical and outcomes data 
were collected by manual chart abstraction. Patients were divided into two groups: a 
NP-based treatment group and a non- NP-based treatment group. Overall (OS) and 
progression-free (PFS) survival were estimated using Kaplan–Meier method. Cox 
proportional hazards regression was used for multivariate analyses. Results: A total 
of 120 patients received second-line chemotherapy. There were 47(39%) patients in 
the NP group and 73 (61%) in the non-NP group. As compared to the non-NP group, 
the NP group showed improved median PFS [2.8 vs. 2.1 months; hazard ratio (HR) = 
0.62, 95% confidence interval (CI) = 0.38-1.02; p=0.06] and median OS (7.5 vs. 4.7 
months; HR = 0.67, 95% CI = 0.45-1.00; p=0.05). Multivariate analyses adjusted for 
age showed a significantly improved PFS (adjusted HR = 0.60, 95% CI = 0.36-0.98; 
p=0.04) and a suggestion of improved OS (adjusted HR = 0.67, 95% CI = 0.44-1.01, 
p=0.05) in the NP group as compared to non-NP group. Serious adverse events 
were seen in 13.3% of patients in the non- NP group and 17.1% patients in the NP 
group. Conclusion: In a single-institution retrospective cohort study, we report a 
significant improvement in the PFS and suggestion of improvement in the OS with 
NP-based second-line chemotherapy with an acceptable toxicity rate.   
Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer and is the fourth 
leading cause of cancer-related mortality in the United States (US) (1). In 2017 
alone, 53,670 cases of PDAC are expected, resulting in approximately 43,090 
deaths in the US (2). The median overall survival (OS) of patients with PDAC is 20% 
at 1 year and 8% at 5 years (3). Despite recent progress, there is a clear need to 
improve systemic treatments for PDAC. Recently, nab-paclitaxel (NP) in combination 
with gemcitabine was shown to lead to a clinically meaningful and significant 
improvement in the median OS and median progression-free survival (PFS) when 
compared with gemcitabine alone (4). This has led to the approval of gemcitabine as 
a first-line treatment for PDAC similar to FOLFIRINOX (folinic acid, 5-fluorouracil, 
irinotecan and oxaliplatin), the only other first-line treatment for patients with 
metastatic PDAC (5).  
 In clinical practice, many patients may receive FOLFIRINOX as first-line 
treatment and gemcitabine as the second-line treatment especially in the US (6). 
Many factors influence the decision to select between FOLFIRINOX and gemcitabine 
including age, performance status, associated comorbidities and potential toxicity 
(7). FOLFIRINOX is often chosen for patients with good performance status, age ≤75 
years and lack of or controlled comorbidities (7, 8). Usually in this scenario, 
gemcitabine is the preferred second-line treatment after progression on 
FOLFIRINOX in the absence of prospective data. Alternatively, 5-fluorouracil based 
second-line therapy in combination with nanoparticle liposomal irinotecan (9) or 
oxaliplatin (10, 11) has shown overall survival (OS) benefit in second-line treatment. 
Interestingly, up to 50% of patients with PDAC may be eligible for second-line 
chemotherapy (12, 13).  
 There are no randomized data for the effectiveness of gemcitabine in the 
second-line treatment of PDAC. However, survival benefit with acceptable toxicity 
has been reported by several groups with gemcitabine in patients previously treated 
with FOLFIRINOX (14, 15). Notably, these are single-institution case series with 
small numbers of patients, resulting in selection bias. Additionally, there was no 
comparison group in these studies, which leads to poor internal validity (ability to 
draw causal conclusion between the exposure and outcome). Therefore, we 
conducted a retrospective cohort study with the primary aims of assessing: i) the 
efficacy of NP-based (as compared to non-NP-based) second-line treatment in 
PDAC; ii) assess the toxicity of NP-based (as compared to non-nab-paclitaxel 
based) second-line treatment in PDAC; and iii) reviewing the existing literature for 
the efficacy and toxicity of NP-based second-line chemotherapy in PDAC. 
  
Patients and Methods 
Study population. The Indiana University Simon Cancer Center (IUSCC) pancreatic 
cancer program was used to identify the patients with biopsy-proven diagnosis of 
PDAC between the years 2009-2015. Retrospective as well as prospective data 
collection was carried out on patients with PDAC who were new to IUSCC. Main 
inclusion criteria of the study were age >18 years, diagnosis of PDAC, receipt of 
second-line chemotherapy treatment and available demographic, clinical and 
outcomes data. Patients with diagnosis of neuroendocrine pancreatic cancer were 
excluded. The study was approved by the Institutional Review Board of Indiana 
University (IRB approval number 1409274071). 
 
Data collection. Patients were divided into two groups, NP-based treatment group 
and non-NP-based treatment group. Manual chart abstraction was used in addition 
to IUSCC cancer registry to gather the demographic, clinical and outcomes data. 
Both paper and electronic medical records were reviewed to obtain patient’s 
demographic (age, sex, race, family history of malignancy, history of diabetes, 
tobacco use, alcohol use, body mass index), clinical [comorbidities, histology of the 
tumor, carbohydrate antigen (CA-19-9) and bilirubin levels at presentation, location 
of the tumor, Eastern Cooperative Oncology Group performance status, number of 
metastatic sites, adjuvant chemotherapy, pathological staging (American Joint 
Committee on Cancer) of the tumor and whether the patient had undergone surgery 
or radiation therapy) and outcomes (best response, serious toxicity, OS and PFS) 
data. Data was collected and stored in OnCore® database (Forte Research 
Systems, Madison, Wisconsin, USA).  
 
Statistical analyses. Baseline characteristics between the groups that received 
second-line NP-based versus non-NP-based treatment were compared using chi-
square test for categorical variables and Student t-test for continuous variables.  
 
Response evaluation and toxicity assessment. Response was categorized based on 
the best response documented by the treating physician and radiology report as 
partial response, complete response, stable disease or progressive disease. Note 
that the radiological scan interval was based on clinical care. Similarly, toxicity was 
assessed by retrospective chart review and considered serious (grade 3 or 4) if the 
adverse effect resulted in dose reduction, dose delay or holding off of scheduled 
treatment. Individual toxicity assessment (type and grade) was not attempted due to 
the likelihood of incomplete data.  
 
Survival and prognostic effect analyses. OS and PFS were estimated using the 
Kaplan–Meier method. OS was defined as the time from start of second-line 
treatment to death from any cause, whereas PFS was defined as the time from start 
of second-line treatment to either progression of PDAC or death from any cause. 
Survival was compared between the two groups using log-rank test. Censoring 
method was adopted for patients who were lost to follow-up or died. Cox proportional 
hazard regression model was used to estimate the simple and adjusted hazard ratios 
(HR) and 95% confidence interval (95% CI), adjusting for significant variables 
between the two groups. p-Values for differences were considered significant if 0.05 
or less. All statistical analyses were performed using RStudio version 1.0.143 (16). 
 
Results 
Study participants. Between 2009-2015, a total of 120 patients with PDAC were 
treated with second-line chemotherapy, of which 47 (39%) were in the NP group and 
73 (61%) patients were in the non-NP group. The univariate analyses showed that 
the patients in the NP group were significantly younger as compared to the non-NP 
treatment group (median age = 60.4 vs. 64 years respectively, p=0.02). Similarly, a 
lower percentage of patients in the NP group had diabetes mellitus at presentation 
as compared to the non-NP treatment group (26% vs. 49% respectively, p=0.10). 
However, none of the other demographic or clinical characteristics were significantly 
different between the two groups (Table I). 
 In the NP group, most patients received FOLFIRINOX in first-line 
chemotherapy (72%) and gemcitabine in the second-line setting (77%) (Table II). 
However, in the non-NP group, the most common first-line chemotherapy was 
gemcitabine (44%) and 5-FU or capecitabine based chemotherapy was the used in 
second-line treatment (54%). 
 
Response evaluation and toxicity assessment. There were no complete responses. 
A total of eight patients had partial response, three (4.7%) in the non-NP group and 
five (11.5%) in the NP group, respectively. Seventeen and 11 patients had stable 
disease in the non-NP and NP groups resulting in a disease control rate (DCR) of 
31.2% in the non-NP and 36.3% in the NP group. Overall serious adverse events 
were observed in 13.3% of patients of the non-NP group and 17.1% of patients in the 
NP group. 
  
Survival analyses. The PFS analysis included 104 patients, 42 in the NP group and 
62 in the non-NP group. The median PFS was marginally improved in the NP group 
as compared to the non-NP group (2.8 vs. 2.1 months; HR = 0.62; 95% CI=0.38-
1.02; p=0.06). Multivariate analysis adjusted for age showed significantly improved 
PFS in the NP group as compared to the non-NP group (adjusted HR = 0.60, 95% CI 
= 0.36-0.98, p=0.04). 
 The OS analysis included 104 patients, 47 in the NP group and 73 in the non-
NP group. The median OS was significantly better in the NP group as compared to 
the non-NP group (7.5 vs. 4.7 months; HR = 0.67; 95% CI = 0.45-1.00; p=0.05). 
Multivariate analysis adjusted for age showed a suggestion of improved OS in the 
NP group as compared to the non-NP group (adjusted HR = 0.67, 95% CI = 0.44-
1.01, p=0.05). 
 
Discussion 
In this single-institution retrospective cohort study of 120 patients with metastatic, 
locally advanced or recurrent PDAC, we report a significant improvement in the PFS 
and suggestion of improvement in the OS with NP-based chemotherapy as 
compared with non-NP-based chemotherapy in the second-line treatment of PDAC. 
Our study is unique as we compared NP-based chemotherapy to non-NP based 
chemotherapy (mainly 5-FU-based) in the second-line treatment of PDAC. To our 
knowledge, this comparison has not been reported in any other study. Additionally, 
our study is the largest study examining the effect of NP-based second-line 
chemotherapy for PDAC in the existing literature. 
 In the past decade, significant progress has been made in the systemic 
therapy of PDAC, however, there is no current standard for the second-line 
treatment of PDAC. Recently, nanoliposomal irinotecan with fluorouracil and folinic 
acid was shown to confer a survival advantage over fluorouracil and folinic acid in 
patients with PDAC previously treated with gemcitabine-based therapy in a phase III, 
randomized controlled trial (NAPOLI-1) (9). This trial provides level 1 evidence for 
the use of nanoliposomal irinotecan with fluorouracil and folinic acid in patients 
treated with gemcitabine based chemotherapy in the first-line setting (9). However, in 
patients treated with first-line FOLFIRINOX, NP (in combination with gemcitabine) 
might be a better option as is suggested by our data and that of others (14, 15, 17-
19).  
 Several case series from different countries (Table III) have reported their 
experience with second-line NP and gemcitabine therapy. Although 5-fluorouracil-
based chemotherapy has been studied in second-line (9-11) (Table IV), there are no 
randomized trials of NP-based second-line chemotherapy. Therefore, we take the 
opportunity to summarize the existing studies of NP-based chemotherapy in the 
second-line treatment of PDAC and contrast our findings with the existing literature. 
The summarized data argues for a randomized trial to evaluate the sequence of the 
two best existing options of chemotherapy (FOLFIRINOX and gemcitabine) in the 
treatment of PDAC to standardize first- and second-line treatment in patients who 
are otherwise eligible for either therapy.  
 We conducted a thorough English literature search on PubMed and Google 
Scholar using the search terms ‘pancreatic cancer’, ‘pancreatic adenocarcinoma’ or 
‘PDAC’, and ‘second-line NP’, ‘second-line Abraxane’ or ‘second-line chemotherapy’ 
until May 2017. We found a total of eight studies (Table III) reporting the experience 
with second-line NP in patients who were initially treated with FOLFIRINOX. Most of 
these studies are retrospective case series, except for the study by Portal and 
colleagues (14), in which they prospectively enrolled 57 patients to receive NP and 
gemcitabine after progressing on FOLFIRINOX (Table III).  
 Our efficacy and toxicity results are similar to those reported in these case 
series. For instance, the objective response rate in the NP group of our case series 
was 11.5% and the DCR was 36.3%, which is in line with the reported ranges of 7.1-
30% and 24-80%, respectively. Similarly, the median PFS (2.8 months) and the 
median OS (7.5 months) in our study (NP group) was consistent with the reported 
median PFS (range = 2.5-5.1 months) and OS (range = 5-17 months), respectively.  
 Second-line NP-based chemotherapy has been generally well-tolerated, with 
some studies reporting up to 25% serious (grade 3/4) adverse event rate (18). The 
serious adverse events usually included neutropenia (up to 20%), anemia (in up to 
25%), thrombocytopenia (in up to 25%), neurotoxicity (in up to 13%) and asthenia (in 
up to 9%). We had an overall serious adverse event rate of 17%, again consistent 
with existing literature. Notably, the adverse event rate was greater in the NP group 
as compared to the non-NP group (17.1% vs. 13.3%). Individual toxicity assessment 
could not be carried out in our case series due to lack of availability of such data.  
 Our study has some limitations. Firstly, response evaluation was performed 
using the best response categorized by the treating physician, therefore, this may 
not be as accurate as using Response Evaluation Criteria In Solid Tumors (20). 
However, our results are similar to those reported in other series and we have 
provided robust data for OS to complement the efficacy assessment. Secondly, we 
were unable to provide grading for serious adverse events as per Common 
Terminology Criteria for Adverse Events (21). mainly because this data was not 
available for all our patients. However, available prospective data suggest that NP 
(combined with gemcitabine) is well-tolerated in the second-line treatment of PDAC. 
Thirdly, our study is a retrospective comparison with inherent limitations such as 
confounding and possibly selection bias. However, we have tried to account for 
confounding by carrying out multivariate analysis. Similarly, selection bias was 
minimized by including all patients who received second-line chemotherapy in our 
cohort.  
 
Conclusion 
From a single-institution retrospective cohort study, we report that NP-based 
chemotherapy (in combination with gemcitabine) can extend PFS and possibly OS, 
with an acceptable toxicity rate. Our study is unique due to its large sample size, 
study design and presence of a comparison group. These results are hypothesis-
generating and will help clinicians to counsel patients regarding the prognosis with 
NP-based and non-NP-based therapy in the second-line treatment of PDAC. Our 
results (and others) argue for a randomized trial to evaluate the best sequence of 
FOLFIRINOX and gemcitabine in patients who are eligible for both chemotherapies.  
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Table I. Baseline characteristics of patients in nab-paclitaxel- and non-nab-paclitaxel-
treated groups. 
Variable  Nab-paclitaxel 
group (N=47) 
Non-nab-
paclitaxel group 
(N=73) 
p-Value 
Median age, (range), years 60.4 (37-75) 64 (37-89) 0.02 
Median CA19-9 (range), U/ml 679 (1-88365) 211 (1-112840) 0.30 
Gender, n (%)    
Male 29 (24) 41 (34) 0.60 
Female 18 (15) 32 (27)  
Race, n (%)    
White 41 (34) 64 (53) >0.999 
Other 6 (5) 9 (8)  
Family history of any cancer, n (%) 43 (37) 22 (19) 0.40 
ECOG performance status, n (%)     
0 8 (17) 8 (17) 0.64 
1 19 (40) 10 (21)  
2 2 (4) 1 (2)  
History of diabetes mellitus, n (%) 31 (26) 59 (49) 0.10 
Location of primary tumor, n (%)    
Head 28 (23) 47 (39) 0.66 
Body 8 (7) 14 (12)  
Tail 11 (9) 12 (10)  
Tobacco use, n (%) 26 (22) 36 (31) 0.72 
Alcohol use, n (%) 31 (27) 38 (33) 0.22 
BMI, n (%)    
≤24.9 kg/m2 23 (19) 46 (39) 0.21 
24.9-29.9 kg/m2 18(15) 17 (14)  
≥30 kg/m2 6 (5) 9 (8)  
Jaundice at presentation, n (%) 21 (18) 31 (26) 0.96 
Surgery, n (%) 25 (21) 41 (34) 0.89 
Adjuvant gemcitabine, n (%) 21 (18) 29 (24) 0.73 
CA19-9: Cancer antigen 19-9; ECOG: Eastern Cooperative Oncology Group; BMI: 
Body mass index. 
  
Table II. Details of the first- and second-line chemotherapies in nab-paclitaxel- and 
non-nab-paclitaxel-treated groups.  
Chemotherapy 
regimen 
Nab-paclitaxel group (N=47), 
N (%) 
Non-nab-paclitaxel group 
(N=73), N (%) 
First-line  Second-line First-line Second-line 
FOLFIRINOX 34 (72) 0 15 (21) 6 (8) 
FOLFOX/XELOX 7 (15) 0 6 (8) 17 (23) 
FOLFIRI 1 (2) 0 0 5 (6.8) 
Gemcitabine and 
nab-paclitaxel 
2 (4) 40 (85) 32 (44) 0 
Gemcitabine 2 (4) 0 7 (9) 17 (23) 
Gemcitabine 
combinationsa 
0 0 6 (8) 9 (12) 
5-Fluorouracil/ 
capecitabine 
1 (2) 0 5 (7) 12 (16) 
Other 0 7b (15) 2c (3) 7d (9) 
FOLFIRINOX: 5-fluorouracil, leucovorin, irinotecan and oxaliplatin; FOLFOX/XELOX: 
5-fluorouracil, leucovorin and oxaliplatin/capecitabine and oxaliplatin; FOLFIRI: 5-
fluorouracil, leucovorin and irinotecan. aGemcitabine combinations included erlotinib, 
capecitabine, oxaliplatin or docetaxel combined with gemcitabine. bIncluded nab-
paclitaxel alone (N=6) and nab-paclitaxel combined with pembrolizumab (N=1). 
cIncluded erlotinib and oxaliplatin (N=1), and cyber knife therapy (N=1). dIncluded 
erlotinib (N=1), irinotecan (N=1), cisplatin and capecitabine (N=1) and phase I clinical 
trials [enoticumab (REGN421), idelalisib, sacituzumab govitecan (IMMU-132) or 
AZD6244 hydrogen sulfate; N=4].  
Table III. Case series of patients receiving gemcitabine plus nab-paclitaxel after FOLFIRINOX for metastatic pancreatic 
adenocarcinoma. None of these studies had a control or comparison group. 
Study (Ref) Country Year N ORR (%) DCR (%) Median PFS 
(months) 
Median OS 
(months) 
Grade 3 or 4 toxicity 
Salem et al. 
(abstract only) (22) 
United States 2014 12 8 24 3.3 16.2 Fatigue (all grades) 54% and 
thrombocytopenia (all grades) 
38% 
Zhang et al. (15) United States 2015 28 17.9 46.5 3 5.3 Neutropenia 17.9%, anemia 
25.0%, thrombocytopenia 25% 
Portal et al. (14) France 2015 57 17.5 58 5.1 8.8 Neutropenia 12.5%, neurotoxicity 
12.5%, asthenia 9%, 
thrombocytopenia 6.5% 
Bertocchi et al. (18) Italy 2015 23 17.4 43.5 2.7 5 Total 13%, thrombocytopenia 
17.4%, neutropenia 8.7%, anemia 
8.7% and neuropathy 13% 
Vogl et al. (abstract 
only) (23) 
Austria 2015 33 NR NR 3 6.3 Neutropenia 13%, 
thrombocytopenia17%, 
polyneuropathy 7% 
Caparello et al. (17) Italy 2016 71 7.1 34.2 2.5 6.2 NR 
Suzuki et al. 
(abstract only) (24) 
Japan 2016 5 0 80 4.6 17 Neutropenia 20% 
El Rassy et al. (19) Lebanon 2017 12 30 60 4.9 NR No grade 3/4 toxicity 
Present study United States 2017 120: NP: 47 
vs. non-NP: 
73 
11.5 vs. 4.7 36.3 vs. 31.2 2.8 vs. 2.1* 7.5 vs. 4.7† Total 17.1% vs. 13.3% 
ORR, Objective response rate; DCR, disease control rate; PFS, progression free survival; OS, overall survival; NR, not reported. 
*Adjusted hazard ratio (95% confidence interval) = 0.60, (0.36-0.98), p=0.04; †adjusted hazard ratio (95% confidence interval) = 
0.67 (0.44-1.01), p=0.05. 
  
 Table IV: Summary of phase III, randomized, controlled, studies in the second-line treatment of pancreatic ductal adenocarcinoma. 
Study Country Year Arms N ORR (%) DCR 
(%) 
Median PFS Median OS  Grade   
Months HR CI P Months HR 95% CI P 
Pelzer et al 
CONKO-01 
(11) 
*Terminated 
early 
Germany, 
multicenter 
2011 OFF vs. 
BSC 
46 No 
responses 
NR NR NR NR NR 4.8 vs. 
2.3 
 
0.45 
 
0.24-
0.83 
0.008 None 
Oettle et al 
CONKO-003 
(10) 
Germany, 
multicenter 
2014 OFF 
vs. 
FF 
168 - 
*1 patient 
in FF had 
CR 
- 2.9 vs. 
2.0  
 
0.68 
 
0.5- 
0.94 
0.01 5.9 vs. 
3.3 
 
0.66 
 
0.48 to 
0.91 
0.01 Anem    
Throm  
1.3% 
Neuro   
Wang-Gillam 
et al. 
NAPOLI-1 (9) 
Global, 
multicenter 
2016 Nal-iri + 5-
FU + LLV 
vs. 
5-FU + LLV  
117 
vs. 
119 
16 vs. 1 
 
 
 
 
 
NR 
 
 
 
 
 
 
2.3 vs. 
1.4  
0.68 0.45 
to 
0.78 
0.0002 6.1 vs. 
4.2 
 
 
 
0·67  
 
0·49–
0·92 
0·012 Nal-iri     
Neutro   
fatigu    
13%,   
Anem    
8%  
 
Nal-iri  
vs. 
5-FU + LLV 
151 
vs. 
149 
6 vs. 1 NR 1.7 vs. 
1.4  
 
0.82  
 
0.65-
1.03 
0.1 4.9 vs. 
4.2 
0·99  0·77–
1·28 
 
0·94 
 
Nal-Ir   
21%,  
appet   
neutro   
vomiti  
hypok   
Anem   
Ulrich-Pur et 
al. (25) 
Austria, 
multicenter 
2003 Raltitrexed 
+ irinotecan 
vs. 
raltitrexed  
 
38 16 vs. 0 NR 4 vs. 2.5 NR NR NR 6.5 vs. 
4.3 
 
NR NR NR All 7.9   
21.1 v   
Trans   
vs. 5.3   
10.5 v   
Nause   
vs. 5.3 
 5-FU: 5-Fluorouracil; FF: 5-FU and folinic acid; HR: hazard ratio; OFF: oxaliplatin, folinic acid, and 5-FU 24 h; BSC: best supportive 
care; LLV: L-leucovorin; Nal-iri, nanosomal irinotecan; OS: overall survival; NR, not reported; CR, complete response.  
Figure 1. Kaplan–Meier survival analysis showing hazard ratio (HR) and 95% 
confidence interval (CI) for overall survival with nab-paclitaxel (NP) and non-NP 
groups. 
 
Figure 2. Kaplan–Meier survival analysis showing hazard ratio (HR) and 95% 
confidence interval (CI) for progression-free survival with nab-paclitaxel (NP) and 
non-NP groups. 
 
  
